Pro forma

Genius Group Announces 2023 Financial Results, 150% Pro Forma Revenue Growth to $70.4 million

Retrieved on: 
Mercoledì, Maggio 15, 2024

Pro forma 2023 revenue increased 150% to $70.4 million from $28.1 million in 2022, including revenue from the FatBrain AI transaction.

Key Points: 
  • Pro forma 2023 revenue increased 150% to $70.4 million from $28.1 million in 2022, including revenue from the FatBrain AI transaction.
  • Gross profit increased to $11.9 million or 52% of revenue compared to $8.6 million, or 47% of revenue in 2022.
  • Gross profit increased to $11.9 million or 52% of revenue compared to $8.6 million, or 47% or revenue in 2022.
  • During the year ended December 31, 2023, overall pro forma revenue totaled $70.4 million, compared to $28.1 million in 2022.

Mach Natural Resources LP Reports First Quarter 2024 Results; Declares Quarterly Cash Distribution of $0.75 Per Unit

Retrieved on: 
Lunedì, Maggio 13, 2024

Mach Natural Resources LP (NYSE: MNR) (“Mach” or the “Company”) today reported financial and operating results for the three months ended March 31, 2024.

Key Points: 
  • Mach Natural Resources LP (NYSE: MNR) (“Mach” or the “Company”) today reported financial and operating results for the three months ended March 31, 2024.
  • The Company also reiterated its full year 2024 outlook and announced its quarterly cash distribution.
  • Mach incurred $32 million, or $3.94 per Boe, of gathering and processing expenses in the first quarter of 2024.
  • Mach announced today that the board of directors of its general partner declared a quarterly cash distribution for the first quarter of 2024 of $0.75 per common unit.

Veritone Reports First Quarter 2024 Results

Retrieved on: 
Martedì, Maggio 7, 2024

In prior periods, we provided “Ending Software Customers,” which represented Software Products & Services customers as of the end of each fiscal quarter with trailing twelve-month revenues in excess of $2,400 for both Veritone, Inc. and PandoLogic Ltd. and/or deemed by Veritone to be under an active contract for the applicable periods.

Key Points: 
  • In prior periods, we provided “Ending Software Customers,” which represented Software Products & Services customers as of the end of each fiscal quarter with trailing twelve-month revenues in excess of $2,400 for both Veritone, Inc. and PandoLogic Ltd. and/or deemed by Veritone to be under an active contract for the applicable periods.
  • Financial Results for Three Months Ended March 31, 2024
    Delivered first quarter revenue of $31.6 million, an increase of $1.3 million or 4.3% from $30.3 million in the first quarter of 2023.
  • Veritone will hold a conference call to deliver management’s prepared remarks on Tuesday, May 7, 2024, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss its first quarter 2024 results, provide an update on the business and conduct a question-and-answer session.
  • To participate, please join the audio webcast or dial-in and ask to be connected to the Veritone earnings conference call.

Nuvei Announces First Quarter 2024 Results

Retrieved on: 
Martedì, Maggio 7, 2024

MONTREAL, May 7, 2024 /PRNewswire/ -- Nuvei Corporation ("Nuvei" or the "Company") (Nasdaq: NVEI) (TSX: NVEI), the Canadian fintech company, today reported its financial results for the three months ended  March 31, 2024. The Company's results are also included in a quarterly shareholder letter which can be found in the "Events and presentations" and "Financial information" sections of the Company's Investor Relations website at https://investors.nuvei.com.

Key Points: 
  • MONTREAL, May 7, 2024 /PRNewswire/ -- Nuvei Corporation ("Nuvei" or the "Company") (Nasdaq: NVEI) (TSX: NVEI), the Canadian fintech company, today reported its financial results for the three months ended  March 31, 2024.
  • SMB revenue increased 1% year over year on a pro forma(a) basis, to $79 million and represented 24% of total revenue in the first quarter.
  • In summary, total revenue increased 11% year over year on a pro forma(a) basis in the first quarter.
  • Nuvei today announced that its Board of Directors has authorized and declared a cash dividend of $0.10 per Subordinate Voting Share and Multiple Voting Share, payable on June 6, 2024 to shareholders of record on May 21, 2024.

UpHealth Provides Corporate Update and Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Giovedì, Marzo 21, 2024

DELRAY BEACH, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- UpHealth, Inc. (“we,” “UpHealth,” or the “Company”) (OTC: UPHL) today provided a corporate update and announced financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • “In short, 2023 was a challenging, yet transformative, year for UpHealth, as we continued to take steps to stabilize the business,” said Martin Beck, Chief Executive Officer.
  • Growth in proforma revenues in the fourth quarter of 2023 was driven by top line growth at TTC Healthcare and Cloudbreak and by certain non-recurring revenues associated with the cessation of operations at Thrasys;
    Proforma fourth quarter 2023 gross margins were 62%, compared to 45% for the fourth quarter of 2022.
  • Proforma margin improvement in the fourth quarter was largely driven by an improved payor mix at TTC Healthcare;
    Proforma fourth quarter 2023 Adjusted EBITDA was $11.1 million, compared with $1.9 million in the fourth quarter of 2022.
  • TTC Healthcare’s performance in 2023, and in particular the fourth quarter 2023, was driven by strong volumes and a significantly improved payor mix.

Veritone Reports Fourth Quarter and Fiscal Year 2023 Results

Retrieved on: 
Martedì, Marzo 12, 2024

Financial Results for Three Months Ended December 31, 2023

Key Points: 
  • Financial Results for Three Months Ended December 31, 2023
    Delivered fourth quarter revenue of $34.2 million, a decrease of $9.7 million or 22.1% from $43.9 million in the fourth quarter of 2022.
  • Financial Results Full Year Ended December 31, 2023
    Delivered fiscal year 2023 revenue of $127.6 million, a decrease of $22.2 million or 14.8% year over year.
  • Revenue is expected to be in the range of $134.0 million to $142.0 million, as compared to $127.6 million for fiscal 2023.
  • Non-GAAP net loss is expected to be in the range of $11.0 million to $15.0 million, compared to non-GAAP net loss of $37.5 million for fiscal 2023.

IQST - iQSTEL Finalizes and Closes QXTEL Acquisition Taking Forecasted Annual Revenue to Quarter of a Billion and One Step Closer to Nasdaq

Retrieved on: 
Giovedì, Aprile 4, 2024

The addition of QXTEL to the iQSTEL group of companies will have a positive impact on the organization's operational results.

Key Points: 
  • The addition of QXTEL to the iQSTEL group of companies will have a positive impact on the organization's operational results.
  • In terms of Revenue, QXTEL will add an estimated $20 million in revenue per quarter, and will also add close to an additional $1 million per quarter in Gross Profit.
  • The QXTEL acquisition is a major milestone for iQSTEL, marking the company's official acquisition of one of the most elite wholesale telecom companies with over a quarter billion in revenue.
  • The acquisition agreement is designed to uphold the current operations of QXTEL independently, ensuring seamless continuity in customer relationships & company operations.

IQST - iQSTEL Announces Record Breaking Revenue and Gross Margin Reaching $46M YTD Revenue Before End of Q1

Retrieved on: 
Giovedì, Marzo 21, 2024

$46 million is a new record high quarterly revenue with two weeks still left to go in the quarter.

Key Points: 
  • $46 million is a new record high quarterly revenue with two weeks still left to go in the quarter.
  • Q1-2024 will be the third straight consecutive revenue record breaking quarter in a row.
  • At the same time, the YTD gross margin has already exceeded the gross margin for the entire 4th Qtr.
  • iQSTEL previously announced that Q4-FY2023 gross margin was a record high exceeding the previous record set in Q3-FY2023.

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

Retrieved on: 
Mercoledì, Febbraio 28, 2024

Selling, general and administrative (SG&A) expenses for the year 2023 were $144.5 million, compared to $123.1 million for the year 2022.

Key Points: 
  • Selling, general and administrative (SG&A) expenses for the year 2023 were $144.5 million, compared to $123.1 million for the year 2022.
  • The fourth quarter basic and diluted loss per share was $0.40, compared to $0.64 for the fourth quarter of 2022.
  • Topline data from the Phase 2 portion of the trial is expected to be available by the fourth quarter of 2024.
  • Immunocore will host a conference call today, February 28, 2024 at 8:00 A.M. ET/ 1:00 PM GMT, to discuss the fourth quarter and full year 2023 financial results and provide a business update.

IQST - iQSTEL Announces $33 Million YTD Revenue and April 1st Target Date to Close QXTEL Acquisition Taking Revenue to Quarter of Billion Annually

Retrieved on: 
Martedì, Marzo 5, 2024

NEW YORK, March 5, 2024 /PRNewswire/ -- iQSTEL Inc. (OTC-QX: IQST) today announced the company's YTD revenue through the end of February 2024, based on preliminary accounting, reached $33 million.

Key Points: 
  • NEW YORK, March 5, 2024 /PRNewswire/ -- iQSTEL Inc. (OTC-QX: IQST) today announced the company's YTD revenue through the end of February 2024, based on preliminary accounting, reached $33 million.
  • iQSTEL management also reports that the company's gross margin YTD continues to trend up in conjunction with the company's forecast.
  • While the revenue reported today does not include any benefit from the QXTEL acquisition agreement, iQSTEL management has set April 1st as the target date for closing the acquisition.
  • "In less than 30 days, we expect iQSTEL to officially be a quarter of a billion dollar in annual revenue company," said Leandro Iglesias, iQSTEL CEO.